Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Ovid Therapeutics ( (OVID) ) is now available.
On March 17 and 18, 2026, Ovid Therapeutics detailed a $60 million private placement and new clinical data that together underpin an expanded epilepsy pipeline. The company agreed to sell 19.2 million common shares and pre‑funded warrants for another 10.7 million shares in a PIPE financing, which is expected to close around March 19, 2026, and will fund broader development of OV329 as well as general R&D.
Ovid reported that a 7 mg cohort of OV329 in Phase 1 showed a favorable safety and tolerability profile with only mild, transient adverse events and no treatment-related serious events, supporting dose selection for upcoming patient studies in focal onset seizures. The company is also moving OV329 into additional rare pediatric epilepsies, including tuberous sclerosis complex seizures and infantile spasms, while initiating a pediatric formulation program that could support an accelerated path and enhance its positioning in severe epilepsy markets.
The company further advanced its KCC2 portfolio, securing Australian ethics and regulatory clearance to start a Phase 1 trial of OV4071 in the second quarter of 2026, initially targeting psychosis associated with Parkinson’s disease and Lewy body dementia. With $90.4 million in cash, cash equivalents and marketable securities at December 31, 2025, and potential warrant exercises, Ovid expects to fund OV329 and OV4071 studies and operations into late 2028, extending its runway as it pursues multiple near-term clinical milestones.
The most recent analyst rating on (OVID) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
The score is primarily held back by weak financial performance (large ongoing losses and heavy cash burn) and limited support from traditional valuation metrics (negative P/E, no dividend). Technicals are mixed/neutral, while the recent positive Phase 1 update and accelerated oral KCC2 program provides some offsetting upside as an early-stage catalyst.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. is a Nasdaq-listed biopharmaceutical company focused on developing small-molecule medicines for brain disorders with significant unmet need, including refractory epilepsies, psychoses and other neurodevelopmental and neurodegenerative conditions. Its pipeline centers on OV329, a next-generation GABA-aminotransferase inhibitor, and OV4071, a first-in-class oral direct activator of the CNS-specific potassium-chloride cotransporter 2 (KCC2), with programs targeting both adult and pediatric indications.
Average Trading Volume: 1,632,862
Technical Sentiment Signal: Hold
Current Market Cap: $261.7M
See more data about OVID stock on TipRanks’ Stock Analysis page.